Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue. -- Barrons.com
S&P August Winners and Losers: Kellanova Tops Index After Turbulent Month, SMCI Plunges
Market Whales and Their Recent Bets on ALNY Options
Novavax Gains on FDA Emergency Nod for Updated COVID Shot
Alnylam Tumbles, BridgeBio Gains After Heart Drug Data
Alnylam Pharmaceuticals Analyst Ratings
WHO Chief Tedros Says Mpox Vaccines Could Be Ready For Emergency Use Listing Within Two Weeks; Some Mpox Vaccines Expected To Arrive In Congo In The Next Few Days
Alnylam Says Typo In Presentation Misstated Heart Drug Benefit
Alnylam Pharmaceuticals Shares Are Trading Lower. The Company Announced Results From Its HELIOS-B Phase 3 Study of Vutrisiran, an Investigational RNAi Therapeutic in Development for the Treatment of ATTR Amyloidosis With Cardiomyopathy.
Alnylam Falls After Full Data for Heart Drug That Can Rival Pfizer's
Amgen Unusual Options Activity For August 29
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
J&J Submits FDA Application for Myasthenia Gravis Drug Nipocalimab
Intuit, Amgen And Sprott Uranium Miners ETF: CNBC's 'Final Trades'
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Key Economic Data
New Medicare Drug Price Caps Could Help Seniors Save Over $1,000 a Year - AARP